Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha to Beta Cell Communication in Health and Disease
NCT07224334Phase 1Recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of exendin 9-39 in diabetes mellitus (DM) (7 arms). Primary endpoint: Insulin secretion with and without exendin-9. Started Dec 2025; status: recruiting.
02
Drugs
exendin 9-39
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT07224334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224334.